Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Clovis Oncology

DB:C6O
Snowflake Description

High growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
C6O
DB
$448M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • Clovis Oncology has significant price volatility in the past 3 months.
C6O Share Price and Events
7 Day Returns
-15.1%
DB:C6O
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-75.8%
DB:C6O
-13.2%
DE Biotechs
-20.9%
DE Market
C6O Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Clovis Oncology (C6O) -15.1% -25.5% -28.4% -75.8% -89.7% -93.5%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • C6O underperformed the Biotechs industry which returned -13.2% over the past year.
  • C6O underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
C6O
Industry
5yr Volatility vs Market

C6O Value

 Is Clovis Oncology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Clovis Oncology is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Clovis Oncology has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Clovis Oncology. This is due to cash flow or dividend data being unavailable. The share price is €5.391.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Clovis Oncology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Clovis Oncology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:C6O PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-7.43
NasdaqGS:CLVS Share Price ** NasdaqGS (2020-04-03) in USD $6.1
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Clovis Oncology.

DB:C6O PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:CLVS Share Price ÷ EPS (both in USD)

= 6.1 ÷ -7.43

-0.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Clovis Oncology is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Clovis Oncology is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Clovis Oncology's expected growth come at a high price?
Raw Data
DB:C6O PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
43.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Clovis Oncology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Clovis Oncology's assets?
Raw Data
DB:C6O PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-3.17
NasdaqGS:CLVS Share Price * NasdaqGS (2020-04-03) in USD $6.1
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:C6O PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:CLVS Share Price ÷ Book Value per Share (both in USD)

= 6.1 ÷ -3.17

-1.92x

* Primary Listing of Clovis Oncology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Clovis Oncology has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at Clovis Oncology's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Clovis Oncology's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Clovis Oncology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Clovis Oncology has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

C6O Future Performance

 How is Clovis Oncology expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
43.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Clovis Oncology expected to grow at an attractive rate?
  • Clovis Oncology's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Clovis Oncology's earnings growth is expected to exceed the Germany market average.
  • Clovis Oncology's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:C6O Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:C6O Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 43.8%
DB:C6O Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 30.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:C6O Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:C6O Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 719 129 5
2023-12-31 576 118 -27 6
2022-12-31 405 -86 -193 7
2021-12-31 283 -191 -241 8
2020-12-31 191 -290 -327 9
2020-04-06
DB:C6O Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 143 -324 -400
2019-09-30 134 -336 -400
2019-06-30 119 -352 -396
2019-03-31 110 -364 -377
2018-12-31 95 -366 -368
2018-09-30 82 -349 -321
2018-06-30 76 -322 -291
2018-03-31 67 -281 -366
2017-12-31 56 -261 -346
2017-09-30 39 -250 -365
2017-06-30 22 -265 -370
2017-03-31 7 -263 -324

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Clovis Oncology's earnings are expected to grow significantly at over 20% yearly.
  • Clovis Oncology's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:C6O Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Clovis Oncology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:C6O Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.91 2.42 -0.03 4.00
2023-12-31 -0.28 1.53 -1.87 5.00
2022-12-31 -2.23 -1.32 -2.99 6.00
2021-12-31 -3.06 -1.42 -4.14 9.00
2020-12-31 -4.74 -3.92 -6.44 10.00
2020-04-06
DB:C6O Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -7.43
2019-09-30 -7.50
2019-06-30 -7.49
2019-03-31 -7.16
2018-12-31 -7.07
2018-09-30 -6.24
2018-06-30 -5.78
2018-03-31 -7.51
2017-12-31 -7.36
2017-09-30 -8.26
2017-06-30 -8.90
2017-03-31 -8.13

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Clovis Oncology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Clovis Oncology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Clovis Oncology has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

C6O Past Performance

  How has Clovis Oncology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Clovis Oncology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Clovis Oncology does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Clovis Oncology's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Clovis Oncology's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Clovis Oncology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Clovis Oncology Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:C6O Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 143.01 -400.42 182.77 283.15
2019-09-30 134.05 -400.18 186.75 281.88
2019-06-30 119.21 -395.97 187.43 267.87
2019-03-31 109.98 -376.74 184.27 249.84
2018-12-31 95.39 -368.01 175.78 231.35
2018-09-30 82.08 -320.63 165.16 198.16
2018-06-30 76.13 -291.43 157.67 173.19
2018-03-31 66.99 -365.63 148.96 153.59
2017-12-31 55.51 -346.40 138.91 142.50
2017-09-30 38.55 -365.24 112.57 158.93
2017-06-30 21.74 -370.27 86.73 174.35
2017-03-31 7.12 -324.20 60.13 208.97
2016-12-31 0.08 -349.14 40.73 251.13
2016-09-30 -397.95 36.78 272.67
2016-06-30 -430.90 35.95 294.47
2016-03-31 -373.12 33.60 287.11
2015-12-31 -352.86 30.52 269.25
2015-09-30 0.00 -288.23 27.89 243.41
2015-06-30 0.00 -229.22 24.83 202.23
2015-03-31 0.00 -192.46 22.89 170.30
2014-12-31 13.63 -160.03 21.46 137.71
2014-09-30 13.63 -134.33 19.20 110.10
2014-06-30 13.63 -115.01 18.24 91.20
2014-03-31 13.63 -99.58 16.47 78.57
2013-12-31 -84.53 16.57 66.55
2013-09-30 -76.39 13.79 61.09
2013-06-30 -74.34 12.24 60.48

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Clovis Oncology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Clovis Oncology has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Clovis Oncology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Clovis Oncology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Clovis Oncology has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

C6O Health

 How is Clovis Oncology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Clovis Oncology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Clovis Oncology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Clovis Oncology's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Clovis Oncology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Clovis Oncology has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Clovis Oncology Company Filings, last reported 3 months ago.

DB:C6O Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -174.26 679.74 296.66
2019-09-30 -87.50 664.04 354.10
2019-06-30 -29.98 583.66 315.91
2019-03-31 74.85 576.00 406.78
2018-12-31 146.47 575.47 520.15
2018-09-30 233.67 574.83 604.38
2018-06-30 312.35 574.34 682.24
2018-03-31 306.24 282.73 463.81
2017-12-31 367.64 282.41 563.73
2017-09-30 299.19 282.08 627.97
2017-06-30 343.79 281.76 671.53
2017-03-31 174.21 281.44 408.83
2016-12-31 -3.63 281.13 266.18
2016-09-30 57.04 280.81 318.78
2016-06-30 112.83 280.50 378.50
2016-03-31 232.66 280.19 445.49
2015-12-31 300.65 279.89 528.59
2015-09-30 414.32 287.50 605.89
2015-06-30 199.67 287.50 377.64
2015-03-31 252.59 287.50 433.38
2014-12-31 331.63 278.68 482.68
2014-09-30 388.29 287.50 516.59
2014-06-30 441.61 0.00 273.23
2014-03-31 472.74 0.00 303.65
2013-12-31 497.89 0.00 323.23
2013-09-30 345.53 0.00 356.62
2013-06-30 363.00 0.00 372.24
  • Clovis Oncology has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Clovis Oncology's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Clovis Oncology has less than a year of cash runway based on current free cash flow.
  • Clovis Oncology has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 21.3% each year.
X
Financial health checks
We assess Clovis Oncology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Clovis Oncology has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

C6O Dividends

 What is Clovis Oncology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Clovis Oncology dividends. Estimated to be 0% next year.
If you bought €2,000 of Clovis Oncology shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Clovis Oncology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Clovis Oncology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:C6O Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:C6O Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Clovis Oncology has not reported any payouts.
  • Unable to verify if Clovis Oncology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Clovis Oncology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Clovis Oncology has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Clovis Oncology's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Clovis Oncology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Clovis Oncology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Clovis Oncology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

C6O Management

 What is the CEO of Clovis Oncology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Patrick Mahaffy
COMPENSATION $6,267,458
AGE 56
TENURE AS CEO 11 years
CEO Bio

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. on April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Officer of Pharmion GmbH. He founded Pharmion LLC in August 1999 and served as its Chief Executive Officer and President since August 1999. He has significant biotechnology and pharmaceutical executive management experience. From June 1992 to 1998, he served as the Chief Executive Officer and President of NeXagen, Inc., and its successor, NeXstar Pharmaceuticals, Inc. He served at E.M. Warburg, Pincus & Co., LLC since 1986, where served as a Vice President. Mr. Mahaffy is credited for developing corporate partnerships with Eli Lilly and Co., Systemix/Sandoz, Schering AG and Becton, Dickinson and Co. He served as the Chairman of Gritstone Oncology Inc. till May 2018. He has been the Chairman of Flexion Therapeutics, Inc. (formerly, Flexion Development Partners, Inc) since 2009. He served as Chairman of Orexigen Therapeutics, Inc. since April 2016 and its Director since February 2009 until July 27, 2018. He served as the Chairman of Psyadon Pharmaceuticals, Inc. He has been a Director of Flexion Therapeutics, Inc., since 2009; Pharmion LLC, since August 1999 and Clovis Oncology, Inc. since April 20, 2009. He serves as a Trustee of Lewis and Clark College. He served as a Director of NeXstar Pharmaceuticals, Inc. since 1991. He served as a Director of Psyadon Pharmaceuticals, Inc. Mr. Mahaffy received a B.A. in International Affairs from Lewis and Clark College and an M.A. in International Affairs from Columbia University.

CEO Compensation
  • Patrick's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Patrick's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Clovis Oncology management team in years:

4.3
Average Tenure
55
Average Age
  • The tenure for the Clovis Oncology management team is about average.
Management Team

Patrick Mahaffy

TITLE
Co-Founder
COMPENSATION
$6M
AGE
56
TENURE
11 yrs

Gillian Ivers-Read

TITLE
Co-Founder
COMPENSATION
$2M
AGE
65
TENURE
11 yrs

Dan Muehl

TITLE
Executive VP & CFO
COMPENSATION
$2M
AGE
55
TENURE
4.1 yrs

Lindsey Rolfe

TITLE
Executive VP of Clinical
COMPENSATION
$2M
AGE
51
TENURE
4.7 yrs

Paul Gross

TITLE
Chief Compliance Officer
AGE
54
TENURE
4.3 yrs

Breanna Burkart

TITLE
Vice President of Investor Relations & Corporate Communications
TENURE
3.6 yrs

Ann Bozeman

TITLE
Executive Vice President of Human Resources
TENURE
3.6 yrs

Anna Sussman

TITLE
Vice President of Investor Relations
Board of Directors Tenure

Average tenure and age of the Clovis Oncology board of directors in years:

11
Average Tenure
63
Average Age
  • The average tenure for the Clovis Oncology board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Ginger Graham

TITLE
Chairman
COMPENSATION
$357K
AGE
63
TENURE
0.8 yrs

Patrick Mahaffy

TITLE
Co-Founder
COMPENSATION
$6M
AGE
56
TENURE
11 yrs

Ed McKinley

TITLE
Independent Director
COMPENSATION
$370K
AGE
67
TENURE
11.3 yrs

Brian Atwood

TITLE
Independent Director
COMPENSATION
$365K
AGE
66
TENURE
11.3 yrs

Jim Blair

TITLE
Independent Director
COMPENSATION
$370K
AGE
79
TENURE
11.3 yrs

Paul Klingenstein

TITLE
Independent Director
COMPENSATION
$360K
AGE
63
TENURE
11 yrs

Thorlef Spickschen

TITLE
Independent Director
COMPENSATION
$357K
AGE
78
TENURE
11.3 yrs

Keith Flaherty

TITLE
Independent Director
COMPENSATION
$355K
AGE
48
TENURE
7.3 yrs

Bob Azelby

TITLE
Independent Director
COMPENSATION
$539K
AGE
51
TENURE
1.5 yrs

Rick Fair

TITLE
Independent Director
COMPENSATION
$539K
AGE
50
TENURE
1.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
21. Aug 19 Buy James Blair Individual 16. Aug 19 20. Aug 19 40,000 €5.38 €210,457
19. Aug 19 Buy Patrick Mahaffy Individual 16. Aug 19 16. Aug 19 50,000 €5.06 €251,954
16. Aug 19 Buy Thorlef Spickschen Individual 16. Aug 19 16. Aug 19 8,600 €5.11 €43,944
15. Aug 19 Buy Thorlef Spickschen Individual 14. Aug 19 14. Aug 19 9,200 €4.90 €45,078
X
Management checks
We assess Clovis Oncology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Clovis Oncology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

C6O News

Simply Wall St News

C6O Company Info

Description

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Details
Name: Clovis Oncology, Inc.
C6O
Exchange: DB
Founded: 2009
$415,285,101
73,448,619
Website: http://www.clovisoncology.com
Address: Clovis Oncology, Inc.
5500 Flatiron Parkway,
Suite 100,
Boulder,
Colorado, 80301,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS CLVS Common Stock Nasdaq Global Select US USD 16. Nov 2011
DB C6O Common Stock Deutsche Boerse AG DE EUR 16. Nov 2011
BRSE C6O Common Stock Berne Stock Exchange CH CHF 16. Nov 2011
Number of employees
Current staff
Staff numbers
484
Clovis Oncology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 02:15
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.